We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Roche Diagnostics Intends to Form Strategic Partnership with CapitalBio

By LabMedica International staff writers
Posted on 30 Nov 2010
Roche Diagnostics (Basel, Switzerland) and China's premier biochip development company, CapitalBio (Beijing, China) announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide. More...


The new development builds on the genomics and diagnostics expertise of the two companies and it will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.

The partnership plans to focus initially on the research and development of instruments and products to enhance and automate the Roche NimbleGen microarray workflow and the application of this workflow in preventive and personalized diagnostics.

Special focus shall be placed on cooperation in education on the benefits and use of molecular diagnostics that exploit novel technologies involving microarrays and their related products, and next-generation sequencing in both the greater China and international markets. The partnership also plans to establish educational facilities across China for molecular R&D and the application of clinical molecular diagnostics.

"CapitalBio and Roche offer a large number of complementary skills and interests which can be well served through the harnessing of the capabilities of both companies for product research and development, manufacturing, marketing, and distribution in China and for international markets,” said Professor Jing Cheng, CEO of CapitalBio.

Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is a world leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management.

CapitalBio Corporation is China's leading developer and marketer of diagnostic biochips, microarray related instruments, and microarray services. Its range of LuxScan laser confocal microarray scanners, microarray spotters, and related microarray workflow instruments are used widely in many countries. Its active biochips for cell biology studies and dedicated software for data analysis and biomedical data management are also being used increasingly for clinical studies, including oncology studies.

Related Links:

Roche
CapitalBio




New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Pipette Management Software
VIALINK
New
Automated Microscope
dIFine
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.